Modeling amplified p53 responses under DNA-PK inhibition in DNA damage response.

Oncotarget

State Key Laboratory of Pharmaceutical Biotechnology and MOE Key Laboratory of Model Animal for Disease Study, Model Animal Research Center, Nanjing University, Nanjing, 210023, China.

Published: March 2017

During DNA double strand breaks (DSBs) repair, coordinated activation of phosphatidylinositol 3-kinase (PI3K)-like kinases can activate p53 signaling pathway. Recent findings have identified novel interplays among these kinases demonstrating amplified first p53 pulses under DNA-PK inhibition. However, no theoretical model has been developed to characterize such dynamics. In current work, we modeled the prolonged p53 pulses with DNA-PK inhibitor. We could identify a dose-dependent increase in the first pulse amplitude and width. Meanwhile, weakened DNA-PK mediated ATM inhibition was insufficient to reproduce such dynamic behavior. Moreover, the information flow was shifted predominantly to the first pulse under DNA-PK inhibition. Furthermore, the amplified p53 responses were relatively robust. Taken together, our model can faithfully replicate amplified p53 responses under DNA-PK inhibition and provide insights into cell fate decision by manipulating p53 dynamics.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370026PMC
http://dx.doi.org/10.18632/oncotarget.15062DOI Listing

Publication Analysis

Top Keywords

amplified p53
16
dna-pk inhibition
16
p53 responses
12
responses dna-pk
8
p53 pulses
8
pulses dna-pk
8
p53
7
dna-pk
6
inhibition
5
modeling amplified
4

Similar Publications

Targeting p97/Valosin-Containing Protein Promotes Hepatic Stellate Cell Senescence and Mitigates Liver Fibrosis.

DNA Cell Biol

January 2025

Research Center of Integrated Traditional Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China.

Liver fibrosis, one of the main histological determinants of various chronic liver diseases, currently lacks effective treatment. Hepatic stellate cells (HSCs) are pivotal in the production of extracellular matrix and amplify the fibrogenic response. Inhibiting the activation of HSCs or promoting the senescence of activated HSCs is crucial for the regression of liver fibrosis.

View Article and Find Full Text PDF

FLT3 Inhibitors Induce p53 Instability, Driven by STAT5/MDM2/p53 Competitive Interactions in Acute Myeloid Leukemia.

Cancer Lett

January 2025

Pediatric Hematology Laboratory, Division of Hematology/Oncology, Department of Pediatrics, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, China. Electronic address:

Article Synopsis
  • FLT3 mutations are common in AML, making them a key target for therapy, but resistance to FLT3 inhibitors is a significant challenge.
  • Tyrosine kinase inhibitors (TKIs) promote p53 degradation in FLT3-ITD AML cells through mechanisms involving STAT5 and MDM2, disrupting p53's role as a tumor suppressor.
  • Using MDM2 inhibitors alongside TKIs can stabilize p53 levels, enhancing the effectiveness of treatments and suggesting a promising combination approach for AML therapy.
View Article and Find Full Text PDF

Neuroblastoma is the most common extra-cranial solid tumour in children. Over half of all high-risk cases are expected to succumb to the disease even after chemotherapy, surgery, and immunotherapy. Although the importance of MYCN amplification in this disease is indisputable, the mechanistic details remain enigmatic.

View Article and Find Full Text PDF

The worldwide frequency of head and neck squamous cell carcinoma (HNSCC) is approximately 800,000 new cases, with 430,000 deaths annually. We determined that LZK (encoded by ) is a therapeutic target in HNSCC and showed that inhibition with small molecule inhibitors decreases the viability of HNSCC cells with amplified . A drug-resistant mutant of LZK blocks decreases in cell viability due to LZK inhibition, indicating on-target activity by two separate small molecules.

View Article and Find Full Text PDF

Post-transplant G-CSF impedes engraftment of gene-edited human hematopoietic stem cells by exacerbating p53-mediated DNA damage response.

Cell Stem Cell

January 2025

Cellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD 20892, USA. Electronic address:

Article Synopsis
  • Granulocyte-colony-stimulating factor (G-CSF) is used to help patients recover from low white blood cell counts after treatments, but its effect on gene-edited stem cells post-gene therapy is not well studied.* -
  • Research shows that administering G-CSF right after gene therapy negatively impacts the success of gene-edited human stem cells by increasing stress and activating the p53 protein, which is involved in DNA damage response.* -
  • Delaying G-CSF treatment or inhibiting p53 can reduce its harmful effects, highlighting the need for careful consideration of G-CSF in future clinical trials involving CRISPR-Cas9 gene therapy.*
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!